SCHEMBL6507557

SCHEMBL6507557

COCCc1[nH]nc2c1c(=O)[nH]c1ccc(Cl)cc12

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 8/20 0.62
ADORA3 P0DMS8 1/20 0.39
CSF1R P07333 1/20 0.39
CDC25A P30304 1/20 0.39
CDC25C P30307 1/20 0.39
PTGES O14684 1/20 0.38
LMNA P02545 1/20 0.38
EGFR P00533 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
CYP1A2 P05177 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
IDH1 O75874 1/20 0.37
ALDH1A1 P00352 1/20 0.37
PYGL P06737 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513915 0.89 CHEK1 (0.60) CHEK1ADORA3CSF1RCDC25ACDC25C
SCHEMBL6515387 0.88 CHEK1 (0.59) CHEK1ADORA3CSF1RCDC25ACDC25C
SCHEMBL6509924 0.84 CHEK1 (0.70) CHEK1ADORA3CSF1RCDC25ACDC25C
SCHEMBL6509557 0.83 CHEK1 (0.53) CHEK1ADORA3CSF1RPTGESALDH1A1
SCHEMBL6507672 0.82 CHEK1 (0.60) CHEK1ADORA3CSF1RCDC25ACDC25C
SCHEMBL6509456 0.79 CHEK1 (0.51) CHEK1ADORA3CSF1RPTGESALDH1A1
SCHEMBL6507585 0.77 CHEK1 (1.00) CHEK1ADORA3CSF1RCDC25ACDC25C
SCHEMBL6514928 0.77 CHEK1 (0.46) CHEK1HPGDALDH1A1
SCHEMBL6513239 0.72 CHEK1 (0.53) CHEK1LMNAHPGDIDH1ALDH1A1
SCHEMBL6513681 0.72 CHEK1 (0.70) CHEK1MAPK8MAPK9MAPK10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885ADORA3 4827/4885CSF1R 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.